Johns Hopkins study finds personal epigenetic ‘signatures’ consistent in prostate cancer patients’ metastases

Johns Hopkins study finds personal epigenetic ‘signatures’ consistent in prostate cancer patients’ metastases In a genome-wide analysis of 13 metastatic prostate cancers, scientists at the Johns Hopkins Kimmel Cancer Center found consistent epigenetic “signatures” across all metastatic tumors in each patient. The discovery of the stable, epigenetic “marks” that sit on the nuclear DNA of … Continue reading “Johns Hopkins study finds personal epigenetic ‘signatures’ consistent in prostate cancer patients’ metastases”

Johns Hopkins study finds personal epigenetic ‘signatures’ consistent in prostate cancer patients’ metastases

In a genome-wide analysis of 13 metastatic prostate cancers, scientists at the Johns Hopkins Kimmel Cancer Center found consistent epigenetic “signatures” across all metastatic tumors in each patient. The discovery of the stable, epigenetic “marks” that sit on the nuclear DNA of cancer cells and alter gene expression, defies a prevailing belief that the marks vary so much within each individual’s widespread cancers that they have little or no value as targets for therapy or as biomarkers for treatment response and predicting disease severity.

Click here to read full press release.

###

Among the research institutions NCI funds across the United States, it currently designates 67 as Cancer Centers. Largely based in research universities, these facilities are home to many of the NCI-supported scientists who conduct a wide range of intense, laboratory research into cancer’s origins and development. The Cancer Centers Program also focuses on trans-disciplinary research, including population science and clinical research. The centers’ research results are often at the forefront of studies in the cancer field.

 

Author: Joe Lovrek

Born in Houston, Raised in Trinity Texas

Leave a Reply